BACKGROUND: The objective was to quantify the health-related quality of life (HRQL) of children treated for acute lymphoblastic leukemia (ALL) and identify specific disabilities for remediation. PROCEDURE: Two types of subjects were included: ALL patients 5 plus years old in a multi-center clinical trial and general population control groups. Patients were assessed during all four major phases of active treatment and approximately 2 years after treatment. Health status and HRQL were measured using HEALTH UTILITIES INDEX® (HUI®) Mark 2 (HUI2) and Mark 3 (HUI3). HRQL scores were used to calculate quality-adjusted life years (QALYs). Excess disability rates identified attributes for remediation. RESULTS: HUI assessments (n = 749) were collected during the five phases. Mean HRQL increased from induction through the post-treatment phase (P < 0.001). There were no significant demographic or treatment effects on HRQL, except for type of asparaginase during continuation therapy (P = 0.005 for HUI2 and P = 0.007 for HUI3). Differences in mean HRQL scores between patients and controls were important (P < 0.001) during the active treatment phases but not during the post-treatment phase. Relative to controls, patients lost approximately 0.2 QALYs during active treatment. Disability was evident in mobility/ambulation, emotion, self-care and pain, and declined over time. CONCLUSIONS: Patients with ALL experienced important but declining deficits in HRQL during active treatment phases: Equivalent to losing approximately 2 months of life in perfect health. HRQL within the 2-years post-treatment phase was similar to controls. The policy challenge is to develop new treatment protocols producing fewer disabilities in mobility/ambulation, emotion, self-care, and pain without compromising survival.
BACKGROUND: The objective was to quantify the health-related quality of life (HRQL) of children treated for acute lymphoblastic leukemia (ALL) and identify specific disabilities for remediation. PROCEDURE: Two types of subjects were included: ALL patients 5 plus years old in a multi-center clinical trial and general population control groups. Patients were assessed during all four major phases of active treatment and approximately 2 years after treatment. Health status and HRQL were measured using HEALTH UTILITIES INDEX® (HUI®) Mark 2 (HUI2) and Mark 3 (HUI3). HRQL scores were used to calculate quality-adjusted life years (QALYs). Excess disability rates identified attributes for remediation. RESULTS: HUI assessments (n = 749) were collected during the five phases. Mean HRQL increased from induction through the post-treatment phase (P < 0.001). There were no significant demographic or treatment effects on HRQL, except for type of asparaginase during continuation therapy (P = 0.005 for HUI2 and P = 0.007 for HUI3). Differences in mean HRQL scores between patients and controls were important (P < 0.001) during the active treatment phases but not during the post-treatment phase. Relative to controls, patients lost approximately 0.2 QALYs during active treatment. Disability was evident in mobility/ambulation, emotion, self-care and pain, and declined over time. CONCLUSIONS:Patients with ALL experienced important but declining deficits in HRQL during active treatment phases: Equivalent to losing approximately 2 months of life in perfect health. HRQL within the 2-years post-treatment phase was similar to controls. The policy challenge is to develop new treatment protocols producing fewer disabilities in mobility/ambulation, emotion, self-care, and pain without compromising survival.
Authors: R D Barr; A Gonzalez; M Longchong; W Furlong; M P Vizcaino; J Horsman; L Fu; L Castillo Journal: Int J Oncol Date: 2001-08 Impact factor: 5.650
Authors: Lillian Sung; Rochelle Yanofsky; Robert J Klaassen; David Dix; Sheila Pritchard; Naomi Winick; Sarah Alexander; Anne Klassen Journal: Int J Cancer Date: 2011-03-01 Impact factor: 7.396
Authors: G H Verrips; M C Stuifbergen; A L den Ouden; G J Bonsel; R J Gemke; N Paneth; S P Verloove-Vanhorick Journal: J Clin Epidemiol Date: 2001-05 Impact factor: 6.437
Authors: Deborah P Waber; Jennifer Turek; Lori Catania; Kristen Stevenson; Philippe Robaey; Ivonne Romero; Heather Adams; Cheryl Alyman; Christine Jandet-Brunet; Donna S Neuberg; Stephen E Sallan; Lewis B Silverman Journal: J Clin Oncol Date: 2007-11-01 Impact factor: 44.544
Authors: Theodore W Laetsch; Gary Douglas Myers; André Baruchel; Andrew C Dietz; Michael A Pulsipher; Henrique Bittencourt; Jochen Buechner; Barbara De Moerloose; Kara L Davis; Eneida Nemecek; Timothy Driscoll; Francoise Mechinaud; Nicolas Boissel; Susana Rives; Peter Bader; Christina Peters; Himalee S Sabnis; Stephan A Grupp; Gregory A Yanik; Hidefumi Hiramatsu; Heather E Stefanski; Lawrence Rasouliyan; Lan Yi; Sweta Shah; Jie Zhang; Andrew C Harris Journal: Lancet Oncol Date: 2019-10-09 Impact factor: 41.316
Authors: Andrew Garas; Louise A McLean; Cinzia R De Luca; Peter Downie; Maria C McCarthy Journal: Support Care Cancer Date: 2019-03-21 Impact factor: 3.603
Authors: Alicia S Kunin-Batson; Xiaomin Lu; Lyn Balsamo; Kelsey Graber; Meenakshi Devidas; Stephen P Hunger; William L Carroll; Naomi J Winick; Leonard A Mattano; Kelly W Maloney; Nina S Kadan-Lottick Journal: Cancer Date: 2016-03-29 Impact factor: 6.860
Authors: Hannah-Rose Mitchell; Xiaomin Lu; Regina M Myers; Lillian Sung; Lyn M Balsamo; William L Carroll; Elizabeth Raetz; Mignon L Loh; Leonard A Mattano; Naomi J Winick; Meenakshi Devidas; Stephen P Hunger; Kelly Maloney; Nina S Kadan-Lottick Journal: Int J Cancer Date: 2015-09-03 Impact factor: 7.396
Authors: Regina M Myers; Lyn Balsamo; Xiaomin Lu; Meenakshi Devidas; Stephen P Hunger; William L Carroll; Naomi J Winick; Kelly W Maloney; Nina S Kadan-Lottick Journal: Cancer Date: 2014-01-28 Impact factor: 6.860
Authors: Aeltsje Brinksma; Robbert Sanderman; Petrie F Roodbol; Esther Sulkers; Johannes G M Burgerhof; Eveline S J M de Bont; Wim J E Tissing Journal: Support Care Cancer Date: 2015-03-10 Impact factor: 3.603